The drug was authorized to treat mild to moderate COVID-19 in adults who are at high risk of developing severe illness when alternative treatment options are not “not accessible or clinically appropriate,” Merck said.
The authorization is more limited than for Pfizer’s antiviral Paxlovid, which the FDA greenlit Dec. 22. Research shows Merck’s pill reduced the risk of hospitalization or death by 30 percent, while Pfizer’s lowered this risk by 88 percent, according to The New York Times.
The treatment consists of 40 pills taken over five days and should be available within the next few weeks.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
